Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this 
announcement. 
----------------------------------------------------------------------
--------------    




aap Implantate  AG,  a  medical  technology  company  listed  on  the
Frankfurt Stock Exchange in the  Prime Standard segment, achieved  in
the fourth  quarter  of  the  financial  year  2008  -  according  to
preliminary figures - quarterly  sales of EUR 7.1  million (- 24%  to
fourth quarter 2007).  In contrast  to the fourth  quarter 2008,  the
fourth quarter  2007  was  influenced  by  more  orders  from  global
partners. Total sales of the financial year 2008 went up to EUR  31.2
million, a year-to-year increase of 11%.

In  2008,  the  group  companies  active  in  the  field  of  medical
biomaterials ("aap bio implants group"),  achieved sales of EUR  19.4
million (previous year: EUR 18.8 million, + 3%). This development  is
based  on  the  considerably   cautious  customers'  order   behavior
(reduction of inventories) as well as delays in planned approvals  of
new products.

The Berlin  based  trauma  & orthopaedics  division  of  the  company
reached for  the full  financial  year 2008  a strong  organic  sales
increase of 28% to EUR 11.8 million (previous year: EUR 9.2 million).

+-------------------------------------------------------------------+
| In EUR million                 |     2008 |     2007 |    Changes |
|--------------------------------+----------+----------+------------|
| Fourth quarter sales           |      7.1 |      9.4 |      - 24% |
|--------------------------------+----------+----------+------------|
| Financial year sales           |     31.2 |     28.0 |      + 11% |
|--------------------------------+----------+----------+------------|
| *          thereof trauma &    |     11.8 |     9.2* |      + 28% |
|   orthopaedics                 |          |          |            |
|--------------------------------+----------+----------+------------|
| *          thereof aap bio     |     19.4 |    18.8* |       + 3% |
|   implants group               |          |          |            |
|-------------------------------------------------------------------|
| * Variational presentation to the segment report as of 31st of    |
| December 2007 results in the modified presentation of the         |
| distribution of a product.                                        |
+-------------------------------------------------------------------+





The publication  of  the full  annual  financial statements  2008  is
planned for April 17, 2009.
___________
aap is a medical technology  company that develops, manufactures  and
markets biomaterials and  implants for trauma  and orthopaedics.  Its
product portfolio  includes  bone cements,  bone  graft  substitutes,
antibiotical  carriers,  implants  for  fracture  healing  and  joint
replacement. In addition to its  Berlin headquarters the company  has
locations in Dieburg and Obernburg near Frankfurt am Main, Dusseldorf
as well as at Nijmegen in the Netherlands. aap Implantate AG has been
listed in the Prime Standard segment at the Frankfurt stock  exchange
since May 16, 2003.

Please address any queries to:
aap Implantate AG, Nanette Hüdepohl, Investor & Public Relations,
Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9133; fax: +49 30 7501 9290; n.huedepohl@aap.de


 
--- End of Message ---

aap Implantate AG
Lorenzweg 5 Berlin Germany

WKN: 506660; ISIN: 
DE0005066609; Index: CDAX, Prime All Share, TECH All Share;
Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Prime 
Standard in Frankfurter Wertpapierbörse, 
Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, 
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr 
in Niedersächsische Börse zu Hannover, 
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse 
Stuttgart;



Copyright © Hugin AS 2009. All rights reserved.